News & Updates

Among individuals with type 2 diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) does not contribute to increased pancreatic cancer risk, according to a study.

Researchers from the KK Women’s and Children’s Hospital, Singapore found that sentinel lymph node (SLN) mapping is an acceptable and safe alternative to routine lymphadenectomy in the surgical staging of early-stage endometrioid endometrial cancer (EEC).

Antiviral therapy is associated with substantial improvements in long-term overall survival (OS) but severely underutilized after curative hepatic resection in patients with hepatitis B virus (HBV)– or hepatitis C virus (HCV)–related hepatocellular carcinoma (HCC), a real-world study involving predominantly Asian patients has shown.

The next-generation ROS1 and TRK tyrosine kinase inhibitor (TKI) repotrectinib has demonstrated high response rates and durable activity in patients with ROS1 fusion–positive non-small-cell lung cancer (NSCLC), regardless of whether they have previously received ROS1 TKI therapy, according to phase II results of the ongoing registrational TRIDENT-1 trial.

Primary tumour resection (PTR) in combination with chemotherapy (C) appears beneficial to a specific subgroup of patients with unresectable colorectal mucinous adenocarcinoma with liver metastasis (UCR-MAC-LM) compared with PTR or C alone, suggests a study.

Restarting treatment with maintenance olaparib in ovarian cancer patients who had received one prior poly(ADP-ribose) polymerase (PARP) inhibitor and at least two lines of platinum-based chemotherapy results in a modest but significant improvement in progression-free survival (PFS) compared with placebo, results of a phase III study have shown.